Lymphoma Updates With Alan Z. Skarbnik, MD

Oncology / Hematology

Dr. Skarbnik is director of the Lymphoma and CLL and Immune Effector Cell and Experimental Therapeutics Programs and associate director of the Transplantation and Cellular Therapy Program at the Novant Health Cancer Institute. He is also a clinical assistant professor at the University of North Carolina School of Medicine at Chapel Hill.

  • Alan Skarbnik
    Oncology / Hematology

    Dear readers, As we start #ASH2023, I’ll write about fascinating diffuse large B cell lymphoma (DLBCL) abstracts. Fortunately, there’s a lot to choose from. First,…

  • Alan Skarbnik
    Oncology / Hematology

    Dear readers, On our second sunny day of The 65th ASH Annual Meeting and Exposition, I want to share a few more interesting diffuse large…

  • Alan Skarbnik
    Oncology / Hematology

    Dear readers, This wraps another ASH Annual Meeting and Exposition! It was great being in San Diego, California, and enjoying the science. Here are my…

  • Alan Skarbnik
    Oncology / Hematology
    WM, CLL, CAR-T - 1 year(s) ago

    The ASH annual meeting has been great and as it comes close to an end, here are some interesting abstracts.  A doublet combination for the…

  • Alan Skarbnik
    Oncology / Hematology
    DLBCL abstracts - 1 year(s) ago

    Today I selected a few abstracts focusing on DLBCL. An important article focusing on quality of life analysis of the POLARIX study, showing no difference…

  • Alan Skarbnik
    Oncology / Hematology
    FL and PCNSL updates - 1 year(s) ago

    The warm weather and welcoming people make New Orleans a great setting for the annual ASH meeting! Today, I selected a few abstracts on PCNSL…

  • Alan Skarbnik
    Oncology / Hematology

    ASH22 is about to start! For the next few days I will  be selecting posts related to specific subtypes of lymphoma. Today, focusing on Mantle…